Potential New Agents for the Management of Hyperkalemia

Grants

Funding Acknowledgements

The authors would like to thank Drs. Regina Burris and Mark Rocco, Xelay Acumen, Inc., for medical writing support, which was funded by ZS Pharma.DP reports having received travel grants and honoraria from ZS Pharma and being an investigator on the 003 and HARMONIZE trials. MK reports having received consulting honoraria and travel support for investigator and advisory board meetings from ZS Pharma, and being an investigator for the HARMONIZE trial.